Accentuating cardiovascular events in Sibutramine-treated patients

Authors

  • Radeyah Waseem 3rd year MBBS Student, Dow Medical College, Karachi, Pakistan
  • Mahnoor Raza 3rd year MBBS Student, Dow Medical College, Karachi, Pakistan
  • Aleena Aftab 3rd year MBBS Student, Dow Medical College, Karachi, Pakistan

DOI:

https://doi.org/10.47391/JPMA.4261

Abstract

Sibutramine has been used as an anti-obesity drug, sold under the brand name of Meridia, among others. However, it was banned in various countries after a statistically impactful finding that it increases the risk of cardiovascular events even in patients who were not at a predisposed risk. Despite these findings, Sibutramine is still prescribed in Pakistan, in spite of the high prevalence of cardiovascular diseases in our population. In this letter, we have summarized the long-known, and recent findings regarding Sibutramine and have also provided the statistics to empower our reasoning. We believe that this letter will prove to be a valuable asset in spreading awareness regarding Sibutramine within the medical community in Pakistan.

Continuous...

Published

2022-01-05

Issue

Section

Letter to the Editor